Us Antisense Rnai Therapeutics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The U.S. antisense and RNAi therapeutics market consists of antisense oligonucleotides (ASOs), single-stranded DNA molecules that selectively inhibit gene expression, and RNA interference agents, including small interfering RNA (siRNA), which degrade targeted mRNA through double-stranded RNA pathways. Unlike conventional small-molecule drugs, these therapies intervene upstream of protein production, targeting the root genetic cause of disease rather than downstream symptoms. The market's valuation of $4.82 billion in 2025 reflects accumulated clinical successes and a growing portfolio of approved therapies, with projected revenue of $27.75 billion by 2035 indicating an acceleration in both pipeline depth and commercial adoption.

• •Market valued at ~$4.82 billion in 2025, reaching ~$5.087 billion in 2026
• •Projected to reach ~$27.75 billion by 2035 at a 19.13% CAGR
• •Core modalities: antisense oligonucleotides (ASOs) and RNAi/siRNA agents

The primary engine of market expansion is the increasing number of regulatory approvals for antisense and RNAi therapeutics across hard-to-treat disease categories, validating the modality and encouraging further investment. Advances in delivery technologies, particularly improvements in subcutaneous and intrathecal administration routes, are broadening the addressable patient population beyond specialty hospital settings. Additionally, the declining cost of oligonucleotide synthesis and the maturation of conjugation chemistry platforms are making these therapies economically more viable for chronic, large-patient-population indications.

• •Growing pipeline of FDA-approved oligonucleotide drugs validating the modality
• •Delivery technology improvements expanding addressable indications and patient access
• •Rising prevalence of target diseases (neurodegenerative and genetic disorders)

By technology, antisense technology held approximately 70-73% of the U.S. market share in recent years, reflecting its longer commercialization history, while the RNAi/siRNA segment is projected to grow at the fastest pace over the forecast horizon. Intravenous injections currently dominate the administration channel, but subcutaneous delivery is anticipated to be the fastest-growing route due to improved patient convenience and self-administration potential. Therapeutically, neurodegenerative disorders accounted for roughly 70-72% of market share, with the genetic disorders segment expected to expand at a CAGR near 20% through 2034-2035.

• •Antisense technology dominates at ~70-73% share; RNAi segment is the fastest-growing technology
• •Intravenous injections lead in revenue; subcutaneous segment growing at the fastest rate
• •Neurodegenerative disorders hold ~70-72% share; genetic disorders projected at ~20% CAGR

Who are the notable companies in the industry?

The competitive structure of the U.S. antisense and RNAi therapeutics market is characterized as moderately consolidated at the commercial stage, with a small number of established biologic developers holding significant market share due to high barriers to entry, including proprietary oligonucleotide chemistry, delivery platform expertise, and extensive clinical development experience. The production landscape features a mix of large integrated biopharmaceutical companies with internal oligonucleotide manufacturing capabilities and smaller specialty producers focused exclusively on nucleic acid therapeutics. Capacity and technological leadership are concentrated among firms with advanced lipid nanoparticle (LNP) and conjugate delivery platform development, while the downstream manufacturing value chain relies heavily on specialized contract development and manufacturing organizations (CDMOs) with oligo-specific synthesis infrastructure.

• •Moderately consolidated at commercial stage; high barriers driven by proprietary chemistry and delivery platforms
• •Mix of large integrated biopharmaceutical firms and smaller specialty oligonucleotide-focused developers
• •Manufacturing concentrated among players with advanced LNP and conjugate delivery technology and dedicated oligo CDMO capacity

What are the recent trends and outlook?

The market is entering a phase of accelerated diversification, with RNAi therapeutics poised to close the gap on antisense technology as more siRNA-based drugs secure approvals and gain formulary coverage. Next-generation delivery platforms, including GalNAc conjugation for liver targeting and novel LNP formulations for extrahepatic tissues, are expected to unlock new therapeutic areas and expand the addressable market beyond the current neurodegenerative and metabolic focus. Over the 2026-2035 horizon, the convergence of decreasing manufacturing costs, expanding clinical evidence, and broadening reimbursement pathways positions the U.S. antisense and RNAi sector as one of the highest-growth segments within the broader biotechnology industry.

• •RNAi/siRNA segment expected to overtake antisense as the faster-growing technology over the forecast period
• •Next-generation delivery platforms (GalNAc, extrahepatic LNPs) unlocking new therapeutic indications
• •U.S. remains the dominant global market, supported by favorable regulatory and reimbursement frameworks